Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. SILO Pharma Inc. (SILO) Message Board

New Report Says Smoking Amplifies Schizophrenia an

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 138
(Total Views: 210)
Posted On: 06/28/2022 4:50:37 PM
Avatar
Posted By: NetworkNewsWire
New Report Says Smoking Amplifies Schizophrenia and Depression Risk

New research has found that smoking can increase an individual’s risk of developing depression and schizophrenia. According to a report from the University of Bristol, the risk of developing depression goes up by an estimated 53% to 130% while the risk of developing schizophrenia increases by roughly 52% to 127% when you smoke regularly.

The research was shared at the Royal College of Psychiatrists International Congress and will be used to inform the United Kingdom government’s new Tobacco Control Plan.

Researchers will also provide the Parliament of the UK with data on the number of smokers in the country who also grapple with mental-health conditions. At the moment, an estimated 1.6 million smokers in England have depression and anxiety while 230,000 smokers live with serious mental illnesses such as bipolar disorder and schizophrenia.

This new analysis proves that there is a clear relationship between smoking and the prevalence of negative mental health outcomes, including depression, anxiety, and schizophrenia.

Prof. Marcus Munafo of the University of Bristol, who was one of the authors of the study, stated said there was no doubt that smoking had adverse mental-health effects. The biological psychology professor mentioned the bidirectional effects, or the cyclical relationship, between smoking and mental health, explaining that poor mental health pushes people to smoke more and more, which exacerbates their mental-health illnesses, causing them to smoke even more, which makes their mental health deteriorate even further.

The cycle keeps on repeating itself, and in the end, the individual is addicted to smoking and their mental health has gone down the drain. Munafo stated that health-care professionals who work with people dealing with mental-health conditions ought to understand the cyclical nature of smoking and mental health. Reduced rates of smoking would improve both mental and physical health, he concluded.

The Royal College of Psychiatrists’ Public Mental Health Implementation Center and Action on Smoking and Health (ASH) also released a joint report outlining how medical professionals can address the relationship between smoking and negative mental health outcomes.

Royal College of Psychiatrists president Dr. Adrian James reiterated just how serious a smoking addiction can be, stating that it can cause major harm to the mind and body. But with the right support, he said, smokers who suffer from mental-health conditions can quit smoking.

The National Health Service (NHS) has committed to providing support for patients with mental-health conditions who are addicted to smoking. However, this will mostly be limited to smokers suffering from severe mental illness.

The treatments for mental health afflictions being studied by established companies such as Silo Pharma Inc. (OTCQB: SILO) may also play a role in rolling back the dial on psychiatric disorders, which are on the uptick at this time.

NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer




(0)
(0)




SILO Pharma Inc. (SILO) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us